Louis Lau1, Angela M Green1, Angel Balmaseda2, Eva Harris3. 1. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, USA. 2. Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua. 3. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, USA. Electronic address: eharris@berkeley.edu.
Abstract
BACKGROUND: The four dengue virus serotypes (DENV1-4) are responsible for the most prevalent mosquito-borne viral illness in humans. DENV causes a spectrum of disease from self-limiting dengue fever (DF) to severe, life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Antibodies from one infection can contribute to either protection or increased disease severity in a subsequent infection with a distinct DENV serotype. The effectiveness of the antibody response is modulated by both the affinity and avidity of the antibody/antigen interaction. OBJECTIVES: We investigated how antibody avidity developed over time following secondary DENV2 infection across different disease severities. STUDY DESIGN: We analyzed sera from 42 secondary DENV2-infected subjects (DF, n=15; DHF, n=16; DSS, n=11) from a pediatric hospital-based dengue study in Nicaragua. IgG avidity against DENV2 virions was measured in samples collected during acute and convalescent phases as well as 3, 6, and 18 months post-illness using a urea enzyme-linked immunosorbent assay. RESULTS: The data show a significant increase in avidity from acute to convalescent phase followed by a decrease from convalescent phase to 3 months post-symptom onset, then a plateau. Linear regression analysis comparing antibody avidity between disease severity groups over time indicate that individuals with more severe disease (DHF/DSS) experienced greater decay in antibody avidity over time compared to less severe disease (DF), and ROC curve analysis showed that at 18 months post-illness, lower avidity was associated with previously having experienced more severe disease. CONCLUSIONS: These data suggest that increased dengue disease severity is associated with lower antibody avidity at later time-points post-illness.
BACKGROUND: The four dengue virus serotypes (DENV1-4) are responsible for the most prevalent mosquito-borne viral illness in humans. DENV causes a spectrum of disease from self-limiting dengue fever (DF) to severe, life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Antibodies from one infection can contribute to either protection or increased disease severity in a subsequent infection with a distinct DENV serotype. The effectiveness of the antibody response is modulated by both the affinity and avidity of the antibody/antigen interaction. OBJECTIVES: We investigated how antibody avidity developed over time following secondary DENV2 infection across different disease severities. STUDY DESIGN: We analyzed sera from 42 secondary DENV2-infected subjects (DF, n=15; DHF, n=16; DSS, n=11) from a pediatric hospital-based dengue study in Nicaragua. IgG avidity against DENV2 virions was measured in samples collected during acute and convalescent phases as well as 3, 6, and 18 months post-illness using a urea enzyme-linked immunosorbent assay. RESULTS: The data show a significant increase in avidity from acute to convalescent phase followed by a decrease from convalescent phase to 3 months post-symptom onset, then a plateau. Linear regression analysis comparing antibody avidity between disease severity groups over time indicate that individuals with more severe disease (DHF/DSS) experienced greater decay in antibody avidity over time compared to less severe disease (DF), and ROC curve analysis showed that at 18 months post-illness, lower avidity was associated with previously having experienced more severe disease. CONCLUSIONS: These data suggest that increased dengue disease severity is associated with lower antibody avidity at later time-points post-illness.
Authors: Angel Balmaseda; Samantha N Hammond; Yolanda Tellez; Laurel Imhoff; Yoryelin Rodriguez; Saira I Saborío; Juan C Mercado; Leonel Perez; Elsa Videa; Elvis Almanza; Guillermina Kuan; Miguel Reyes; Leyla Saenz; Juan J Amador; Eva Harris Journal: Trop Med Int Health Date: 2006-06 Impact factor: 2.622
Authors: D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak Journal: J Infect Dis Date: 2000-01 Impact factor: 5.226
Authors: Ananda Nisalak; Timothy P Endy; Suchitra Nimmannitya; Siripen Kalayanarooj; Usa Thisayakorn; Robert M Scott; Donald S Burke; Charles H Hoke; Bruce L Innis; David W Vaughn Journal: Am J Trop Med Hyg Date: 2003-02 Impact factor: 2.345
Authors: Angel Balmaseda; Samantha N Hammond; Leonel Pérez; Yolanda Tellez; Saira Indira Saborío; Juan Carlos Mercado; Ricardo Cuadra; Julio Rocha; Maria Angeles Pérez; Sheyla Silva; Crisanta Rocha; Eva Harris Journal: Am J Trop Med Hyg Date: 2006-03 Impact factor: 2.345
Authors: Federico Narvaez; Gamaliel Gutierrez; Maria Angeles Pérez; Douglas Elizondo; Andrea Nuñez; Angel Balmaseda; Eva Harris Journal: PLoS Negl Trop Dis Date: 2011-11-08